Rabeh Khairy Saleh

Dr. Rabeh Khairy Saleh

Faculty of Medicine, Minia University, Minya, Egypt
orcid
Lecturer at Faculty of Medicine, Minia University, Egypt. Sp...

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2024 in Biochemical Pharmacology
Verified
Journal Article
Closed access
RMReham Hassan Mohyeldein
Reham Hassan Mohyeldein
WAWalaa Yehia Abdelzaher
Walaa Yehia Abdelzaher
ESEhab Essam Sharata
Ehab Essam Sharata
HMHamza M.A. Mohamed
Hamza M.A. Mohamed
MAMohamed Y.M. Ahmed
Mohamed Y.M. Ahmed
RRRemon Roshdy Rofaeil
Remon Roshdy Rofaeil

18 March 2024 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
OMOsama Nady Mohamed Mohamed
Osama Nady Mohamed Mohamed
SISharehan Abdelrahman Ibrahim
Sharehan Abdelrahman Ibrahim
Rabeh Khairy SalehRabeh Khairy Saleh
Rabeh Khairy Saleh
AIAhmed S. Issa
Ahmed S. Issa
ASAmr Setouhi
Amr Setouhi
SKShaimaa F. Kamel
Shaimaa F. Kamel
Background: Globally, there are regional and time-based variations in the prevalence, etiology, and prognosis of rapidly progressive glomerulonephritis (RPGN). Prognosis of RPGN is poor, with a higher risk of death and end stage renal disease (ESRD) even with immunosuppressive medications. In the Middle East and North Africa, the studies on this disease are very limited. Therefore, we determined the predictors of outcome of RPGN. Methods: We retrospectively assessed 101 adult patients over age of 18, diagnosed with RPGN based on renal biopsy illustrating crescents in ≥ 50% of the glomeruli. Patients who had crescents in their renal biopsies that were < 50% and those who refused to consent to a renal biopsy were excluded. We categorized the patients into 3 groups based on immunohistochemistry; type I, type II and type III. Then, depending on renal loss, we divided them into ESRD and non-ESRD groups. The clinical history and physical examination were retrieved. Additionally, 24-hour urine protein, urine analysis, renal function tests, serum albumin, complete blood count, antinuclear antibodies, anti-double stranded DNA antibodies, ANCA antibodies and serum complement levels were checked. Each patient underwent a kidney biopsy for immunohistochemistry and light microscopy. The percentage of crescentic glomeruli, number of sclerosed glomeruli, tertiary lymphoid organ (TLO), neutrophil infiltration, endocapillary or mesangial hypercellularity, interstitial fibrosis with tubular atrophy (IFTA) were analyzed. Primary outcomes (remission, ESRD and mortality) and secondary outcomes were assessed. Results: Type II was the most frequent cause of RPGN (47.5%), followed by type III (32.7%) and type I (19.8%). 32 patients (31.7%) died during follow up, whereas 60 patients (59.4%) developed ESRD. In 41 patients (40.6%), remission occurred. Oliguria, serum creatinine, and need for HD at presentation were significantly increased in ESRD group compared to non-ESRD group (P < 0.001 for each). Mesangial proliferation, IFTA, TLO formation, sclerotic glomeruli and fibrous crescents were also significantly increased in ESRD group in comparison to non-ESRD group (P < 0.001 for each). Glomerulosclerosis (P = 0.036), and IFTA (P = 0.008) were predictors of ESRD. Infections (P = 0.02), respiratory failure (P < 0.001), and heart failure (P = 0.004) were mortality risk factors. Conclusion: Type II RPGN was the most common. Infection was the most frequent secondary outcome. Oliguria, glomerulosclerosis, the requirement for hemodialysis at presentation, IFTA and TLO formation were predictors of ESRD. Respiratory failure, heart failure and infections were significant predictors of mortality.

10 August 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NSNardien Ekram Haliem Saleh
Nardien Ekram Haliem Saleh
MIMariam Yahia Ibrahim
Mariam Yahia Ibrahim
ASAdel Hussein Saad
Adel Hussein Saad
EAElshymaa A. Abdel-Hakeem
Elshymaa A. Abdel-Hakeem
Rabeh Khairy SalehRabeh Khairy Saleh
Rabeh Khairy Saleh
WHWagdy N. Habeeb
Wagdy N. Habeeb
Consumption of high-caloric diets contributes to the alarming number of overweight and obese individuals worldwide, which in turn leads to several diseases and multiple organ dysfunction. Not only has the number of calories taken per day but also the type of fat in the diet has an important impact on health. Accordingly, the purpose of the current study was to examine the impact of different types of high-caloric fat diets on the metabolic status and the integrity of the liver and aorta in albino rats. Adult male albino rats were divided into 6 groups: Control group, long chain-saturated fat group (SFD), long chain-monounsaturated fat (MUFAs) group, long chain-polyunsaturated fat (PUFAs) group, medium-chain fat (MCFAs) group, and short-chain fat (SCFAs) group. Body mass index (BMI), Lee index, and visceral fat amount were reported. Serum levels of insulin, liver transaminases, lipid profile, and different oxidative stress and inflammatory markers were evaluated. Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), and adiponectin/leptin ratio were also calculated. Histopathological examinations of liver and aorta with Masson’s trichrome stain, and immune-staining for Nuclear Factor Erythroid-2-Related Factor-2 (Nrf2) were also done. SFD group showed significantly elevated liver transaminases, inflammatory markers, HOMA-IR, dyslipidemia, reduced adiponectin, and deficient anti-oxidative response compared to other groups together with disturbed hepatic and aortic architecture. Other treated groups showed an improvement. PUFAs group showed the highest level of improvement. Not all high-fat diets are hazardous. Diets rich in PUFAs, MUFAs, MCFAs, or SCFAs may protect against the hazards of high caloric diet.

24 May 2019 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
MRMaggie M. Ramzy
Maggie M. Ramzy
AAAhlam M. Abdalla
Ahlam M. Abdalla
NZNagwa M. Zenhom
Nagwa M. Zenhom
AOAhmed M. Okasha
Ahmed M. Okasha
AAAya E. Abdelkafy
Aya E. Abdelkafy
Rabeh Khairy SalehRabeh Khairy Saleh
Rabeh Khairy Saleh

8 July 2024 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
MAMaha Mohammed Abdel-Fattah
Maha Mohammed Abdel-Fattah
AAAhmed Mamdouh Ahmed
Ahmed Mamdouh Ahmed
Rabeh Khairy SalehRabeh Khairy Saleh
Rabeh Khairy Saleh
BMBasim Anwar Shehata Messiha
Basim Anwar Shehata Messiha
RRRemon Rofaeil
Remon Rofaeil

28 January 2026 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
MMMostafa M. Mohammed
Mostafa M. Mohammed
MRMaggie M. Ramzy
Maggie M. Ramzy
SGShereen S. Gaber
Shereen S. Gaber
SASara G. Ahmed
Sara G. Ahmed
Rabeh Khairy SalehRabeh Khairy Saleh
Rabeh Khairy Saleh
HMHatem A. Mohamed
Hatem A. Mohamed